Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALPG | P10696 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565095 | 0.87 | ESR1 (0.43) | ALDH1A1CYP11B1CYP11B2ESR1ESR2 | |
| SCHEMBL955060 | 0.80 | TYR (0.41) | LMNASMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL958687 | 0.78 | ALDH1A1 (0.44) | LMNASMN1; SMN2ALDH1A1TDP1CYP11B1 | |
| SCHEMBL7967104 | 0.77 | ESR1 (0.47) | LMNASMN1; SMN2ALDH1A1ALPGTDP1 | |
| SCHEMBL4160843 | 0.76 | ALOX5 (0.41) | SMN1; SMN2ALDH1A1HPGDCYP11B1CYP11B2 | |
| SCHEMBL6141138 | 0.76 | IDO1 (0.38) | LMNASMN1; SMN2ALDH1A1ALPGTDP1 | |
| SCHEMBL12263781 | 0.76 | ESR1 (0.36) | ALDH1A1CYP11B1CYP11B2ESR1ESR2 | |
| SCHEMBL4145904 | 0.76 | MEN1 (0.38) | SMN1; SMN2ALDH1A1TDP1HPGDHTT | |
| SCHEMBL909757 | 0.76 | ADRB2 (0.50) | LMNASMN1; SMN2ALDH1A1TDP1HPGD | |
| SCHEMBL450037 | 0.76 | ESR1 (0.61) | LMNASMN1; SMN2ALDH1A1TDP1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243208-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| EP-3383838-B1 | PROCESS FOR THE CATALYTIC REVERSIBLE UNSATURATED HYDROCARBON-NITRILE INTERCONVERSION | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-10-25 | — | — | EP | disclosed |
| US-11253499-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | disclosed |
| US-11253499-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | disclosed |
| EP-3668854-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-12 | — | — | EP | disclosed |
| EP-3668854-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-12 | — | — | EP | disclosed |
| EP-3668854-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-20200170997-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200170997-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| CN-111225909-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-1284056-A | Anticonvulsant and sentral nervous system-active bis (fluorophenyl) alkylamides | NPS PHARMA INC (US) | 2001-02-14 | — | — | CN | disclosed |
| EP-1042275-A1 | ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES | NPS PHARMACEUTICALS, INC. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999029657-A1 | ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES | NPS PHARMACEUTICALS, INC. (US) | 1999-06-17 | — | — | WO | disclosed |
| EP-0170316-B1 | ALPHA-ARYL-4-(4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZIN-2(3H)-YL)BENZENEACETONITRILES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-05-30 | — | — | EP | disclosed |
| US-4778887-A | ANTIPROTOZOA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-10-18 | — | — | US | disclosed |
| US-4631278-A | Anti-protozoal α-aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile derivatives, pharmaceutical compositions, and method of use therefor | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-12-23 | — | — | US | disclosed |
| US-4599362-A | 2-aryl-ethyl ether derivatives and insecticidal and acaricidal agents containing said derivatives | MITSUITOATSU CHEMICALS, INC. (JP) | 1986-07-08 | — | — | US | disclosed |
| US-4570005-A | REACTING THE ARYL PROPYL CHLORIDE WITH THE CORRESPONDING ARYL ALCOHOL OR ARYL MERCAPTAN | MITSUITOATSU CHEMICALS INC. (JP) | 1986-02-11 | — | — | US | disclosed |
| EP-0170316-A2 | alpha-Aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benzeneacetonitriles | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-02-05 | — | — | EP | disclosed |
| US-4397864-A | LOW TOXICITY | MITSUITOATSU CHEMICALS INC. (JP) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253499-B2 | Compounds | SDHA, SDHB, FDPS | LMNA 2414/4885SMN1; SMN2 3636/4885ALDH1A1 207/4885 |
| US-20250243208-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | LMNA 3582/4885SMN1; SMN2 4447/4885ALDH1A1 3361/4885 |
| US-20200170997-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | LMNA 2533/4885SMN1; SMN2 4087/4885ALDH1A1 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.